Literature DB >> 19889617

Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.

E N M Overkleeft, R Goldschmeding, F van Reekum, E E Voest, H M W Verheul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19889617     DOI： 10.1093/annonc/mdp472

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

Review 1.  Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

Authors:  Terri S Armstrong; Patrick Y Wen; Mark R Gilbert; David Schiff
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

Review 2.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

3.  Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.

Authors:  Daiei Takahashi; Kiyotaka Nagahama; Yukio Tsuura; Hiroyuki Tanaka; Teiichi Tamura
Journal:  Clin Exp Nephrol       Date:  2011-10-01       Impact factor: 2.801

4.  Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma.

Authors:  Yumiko Okuno; Haruki Kume; Chihiro Hosoda; Yukio Homma
Journal:  Case Rep Med       Date:  2011-10-05

5.  Minimal change disease onset observed after bevacizumab administration.

Authors:  Ramy M Hanna; Eduardo Lopez; James Wilson; Shrinath Barathan; Arthur H Cohen
Journal:  Clin Kidney J       Date:  2015-12-28

6.  Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.

Authors:  Maureen Assayag; Philippe Rouvier; Marion Gauthier; Ghania Costel; Philippe Cluzel; Lucile Mercadal; Gilbert Deray; Corinne Isnard Bagnis
Journal:  BMC Cancer       Date:  2017-11-16       Impact factor: 4.430

7.  Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report.

Authors:  Yoshitaka Furuto; Hirotsugu Hashimoto; Akio Namikawa; Haruki Outi; Hiroko Takahashi; Hajime Horiuti; Kazuho Honda; Yuko Shibuya
Journal:  BMC Nephrol       Date:  2018-10-19       Impact factor: 2.388

8.  Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity.

Authors:  Wojciech K Jankiewicz; Scott D Barnett; Anna Stavniichuk; Sung Hee Hwang; Bruce D Hammock; Jawad B Belayet; A H Khan; John D Imig
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.